-+ 0.00%
-+ 0.00%
-+ 0.00%

ELICIO THERAPEUTICS - TO FOCUS PHASE 3 DEVELOPMENT ON R0 RESECTED POPULATION WITH ADDITIONAL ELI-2 7P DOSING

Reuters·06/15/2026 11:00:01

Please log in to view news